These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18362220)

  • 41. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.
    Geisen C; Watzka M; Sittinger K; Steffens M; Daugela L; Seifried E; Müller CR; Wienker TF; Oldenburg J
    Thromb Haemost; 2005 Oct; 94(4):773-9. PubMed ID: 16270629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Resistance to coumarin derivatives due to mutated vitamin-K enzyme].
    Hermans MH; Poodt J; van Geest-Daalderop JH; Péquériaux NC; Conemans JM
    Ned Tijdschr Geneeskd; 2009; 153():A691. PubMed ID: 19857286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
    Wilms EB; Touw DJ; Conemans JM; Veldkamp R; Hermans M
    J Thromb Haemost; 2008 Jul; 6(7):1224-6. PubMed ID: 18419745
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.
    Yoshizawa M; Hayashi H; Tashiro Y; Sakawa S; Moriwaki H; Akimoto T; Doi O; Kimura M; Kawarasaki Y; Inoue K; Itoh K
    Thromb Res; 2009 Jun; 124(2):161-6. PubMed ID: 19135231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 1173C>T polymorphism in VKORC1 modulates the required warfarin dose.
    Kosaki K; Yamaghishi C; Sato R; Semejima H; Fuijita H; Tamura K; Maeyama K; Yamagishi H; Sugaya A; Dodo H; Tanigawara Y; Takahashi T
    Pediatr Cardiol; 2006; 27(6):685-8. PubMed ID: 17031720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy?
    Goto S
    Circ J; 2010 May; 74(5):850-1. PubMed ID: 20424335
    [No Abstract]   [Full Text] [Related]  

  • 50. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.
    Li T; Lange LA; Li X; Susswein L; Bryant B; Malone R; Lange EM; Huang TY; Stafford DW; Evans JP
    J Med Genet; 2006 Sep; 43(9):740-4. PubMed ID: 16611750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.
    Bodin L; Horellou MH; Flaujac C; Loriot MA; Samama MM
    J Thromb Haemost; 2005 Jul; 3(7):1533-5. PubMed ID: 15978113
    [No Abstract]   [Full Text] [Related]  

  • 52. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
    Rieder MJ; Reiner AP; Gage BF; Nickerson DA; Eby CS; McLeod HL; Blough DK; Thummel KE; Veenstra DL; Rettie AE
    N Engl J Med; 2005 Jun; 352(22):2285-93. PubMed ID: 15930419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
    Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Warfarin resistance.
    Sinxadi P; Blockman M
    Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.